▶ 調査レポート

世界のHPV検査&PAP検査市場

• 英文タイトル:HPV Testing & PAP Test Market - Growth, Trends, and Forecast (2019 - 2024)

Mordor Intelligenceが調査・発行した産業分析レポートです。世界のHPV検査&PAP検査市場 / HPV Testing & PAP Test Market - Growth, Trends, and Forecast (2019 - 2024) / C-MOR-100152資料のイメージです。• レポートコード:C-MOR-100152
• 出版社/出版日:Mordor Intelligence / 2019年9月
• レポート形態:英文、PDF、111ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥629,000 (USD4,250)▷ お問い合わせ
  Multi User¥703,000 (USD4,750)▷ お問い合わせ
  Site License¥888,000 (USD6,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、HPV検査&PAP検査の世界市場について調査・分析し、HPV検査&PAP検査の世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。

Market Overview
The HPV testing & PAP test market is expected to witness rapid growth due to the increasing number of cervical cancer cases across the globe, an increasing number of cervical cancer screening programs and the introduction of advanced technological innovations.

The increasing incidence rate of cervical and vaginal cancer is the key driver for market growth. Cervical cancer is found to be one of the major causes of cancer-related deaths in women. Each year, more than 13,000 women are diagnosed with cervical cancer in the United States.

According to the CDC statistics, approximately 26,000 new cancers attributable to HPV occur each year, in that 18,000 are of females and 8,000 are of males. The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs. Therefore the increasing number of cases of cervical cancer has boosted the demand for HPV testing and PAP testing market.

There are also government and regional authorities that are implementing certain initiatives that drive the demand for cancer detections tests and kits. For instance, CDC created National Breast and Cervical cancer early detection program that provides free or low-cost screening process for women. WHO has thus framed laws for the elimination of cervical cancer. Hence, increasing government support to create awareness about cervical cancer will boost the market.

Scope of the Report

As per the scope of the report, an HPV is a sexually transmitted infection and can cause abnormal cervical cells that can lead to cervical cancer among the people. HPV has been clinically proven to be the primary cause of cervical cancer. Pap tests are thus found to be the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens. However, these tests are unable to detect all the genotypes causing HPV infections and might also lead to a significant number of false-negative results. Owing to these challenges posed by Pap tests, HPV diagnostic tests were introduced as effective molecular diagnostic tests.

Key Market Trends

Cervical Cancer Screening Test is Anticipated to be the Dominant During the Forecast Period

Cervical cancer screening is found to be an essential part of a woman’s routine health care. The primary goal of screening is to identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.

Cervical cancer screening tests segment is found dominating the segment owing to the increasing awareness about the benefits associated with the early detection of cancer and the growing government support towards controlling the incidence rate of the late-stage cervical cancer. Thus all these factors are found associated with the growth of the market.

North America Region Dominates the Market of HPV Testing & PAP Test Market

North America region has been found dominating the market in terms of revenue due to the increased number of cervical cancer cases and the growing awareness among women due to the various government initiatives and research studies that were undertaken.

According to WHO, cervical cancer is the fourth most frequent cancer in women and in 2018, around 5,70,000 new cervical cases were being diagnosed, thus the rising patient pool will drive the overall market growth. The Centers for Disease Control (CDC) estimates that about 79 million people are currently infected with HPV in the United States, and about 14 million people in the US get infected with new HPV infection every year. Thus the increasing number of cervical cancer cases has boosted the demand for HPV testing and Pap testing market.

Additionally, the favourable trade policies in the U.S. lowers entry barrier for new players willing to capture considerable market share in the HPV testing and Pap test market.

Competitive Landscape

Some key players in the HPV test and Pap test market include Abbott Laboratories, Qiagen, Becton, Dickinson and Company, Roche and many others. The industry players present in the market are found focussing on the strategies such as mergers and acquisitions to expand the existing product portfolio. Also, the receiving approvals from regulatory authorities for new product launches will render the company with a competitive advantage.

Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.

レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cervical Cancer Cases and Growing Aging Population
4.2.2 Increasing Number of Cervical Cancer Screening Programs
4.2.3 Introduction of Advanced Technological Innovations
4.3 Market Restraints
4.3.1 HPV Vaccination
4.3.2 Changes in Regulatory Guidelines for Cervical Cancer Screening
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 HPV Test
5.1.2 PAP Test
5.1.3 Co-Testing
5.1.4 Others
5.2 By Application
5.2.1 Cervical Cancer Screening Test
5.2.2 Vaginal Cancer Screening Test
5.2.3 Others
5.3 By End User
5.3.1 Hospitals/Clinics
5.3.2 Diagnostic centers
5.3.3 Point-of-care
5.3.4 Other settings
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Arbor Vita Corporation
6.1.2 Femasys Inc.
6.1.3 Seegene Inc.
6.1.4 Becton, Dickinson and Company
6.1.5 Quest Diagnostics
6.1.6 Abbott Laboratories
6.1.7 Hologic, Inc.
6.1.8 Qiagen N.V.
6.1.9 F. Hoffmann-La Roche AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS